Email Updates

Search form

You are here

AVAC's Blog: P-Values

  • PrEP took centerstage at the morning plenaries at HIV R4P—and while the talks were going on, the French research agency announced that the IPERGAY trial of intermittent ("on demand") PrEP would be discontinuing randomization and placebo control after strong preliminary evidence of efficacy. This blog post gives a look at both developments.

    October 29, 2014
    AVAC
  • Greetings from the second day of the HIV R4P conference! Each day AVAC will be providing a dispatch with highlights from the conference. Read on for information about the plenary speeches and individual sessions. And we are tweeting all the latest news and photos. Follow us!

    October 29, 2014
  • Eric Mcheka reacts to a presentation by Mitchell Warren during an advocates' workshop. This post was written for the WhatsUpHIV blog, which reported in real time on the 2014 HIV Research for Prevention conference in Cape Town, South Africa.

    October 28, 2014
    Eric Mcheka, 2014 AVAC Advocacy Fellow
  • In this post (first appearing on Breakthroughs, a blog from GHTC), Emily Donaldson—program coordinator at AVAC—and Tom Harmon—senior policy analyst at the International AIDS Vaccine Initiative (IAVI)—write about the state of HIV prevention research funding as the first-ever conference devoted solely to HIV prevention research and development (R&D) takes place in Cape Town, South Africa, this week.

    October 28, 2014
    General
    Emily Donaldson - AVAC
    Tom Harmon - IAVI
  • Greetings from the first official day of the HIV R4P conference! Each day AVAC will be providing a dispatch with highlights from the conference. Read on for information about the plenary speeches and individual sessions. And we are tweeting all the latest news and photos. Follow us!

    October 28, 2014
    AVAC
  • Clinical trials can only achieve their goals if participants use the product. A trial looking at safety or efficacy can’t gather information or draw conclusions if the trial volunteers choose not to follow the protocol—whether it is taking a drug, using a gel or returning for a follow-up injection of a vaccine.
    October 27, 2014
    AVAC
  • The HIV Research for Prevention Conference (HIV R4P) starts on Monday, October 27 in Cape Town, South Africa. We hope that whether on-site or from afar, you will follow along and join the conversation, which will span the range of prevention options (including vaccines, PrEP, microbicides, treatment as prevention, voluntary medical male circumcision and cure) as well as the cross-cutting issues related to trial design and conduct, policy and advocacy.

    October 24, 2014
    AVAC
  • This issue includes a strong series of updates related to the science and policy of new product development and an excellent overview of the state of play of this critical area of work.

    October 23, 2014
    AVAC
  • Last week's announcement from the UK PROUD Study that PrEP was shown to be highly protective could speed up PrEP access in the UK—and change the conversation in Europe.

    October 22, 2014
    AVAC
  • To support the implementation of GPP, AVAC is now pleased to announce an exciting new online training course. This interactive course brings the guidelines to life and gives learners practical skills for applying GPP in their work.

    October 22, 2014
    AVAC

Pages